Related Experiment Video
Updated: Jun 4, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Atrial fibrillation and percutaneous coronary intervention: stroke, thrombosis, and bleeding
Antonio Gutierrez1, Sunil V Rao
1Department of Medicine, Duke University School of Medicine, DUMC 3850, Durham, NC, 27710, USA, antonio.gutierrez@duke.edu.
Insights
Patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI) need oral anticoagulation to prevent mortality and morbidity. Balancing anticoagulation and antiplatelet therapy is crucial to minimize bleeding risk in these high-risk patients.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI) face increased risks of mortality and morbidity without continued oral anticoagulation.
- The necessary combination of oral anticoagulation and dual antiplatelet therapy increases bleeding risk.
Purpose of the Study:
- To outline management strategies for patients with AF undergoing PCI.
- To address the balance between preventing thromboembolism and minimizing bleeding complications.
Main Methods:
- Review of current data and clinical recommendations for AF patients undergoing PCI.
- Emphasis on risk stratification using AF risk scores.
Main Results:
- Bare metal stents are recommended for high-risk AF patients to shorten triple therapy duration.
- Maintaining International Normalized Ratio (INR) at the lower end of the therapeutic range (2.0) and using lower-dose aspirin during triple therapy are advised.
Conclusions:
- Careful management of anticoagulation and antiplatelet therapy is essential for AF patients undergoing PCI.
- Further research is needed on newer oral anticoagulants (e.g., dabigatran, rivaroxaban) in this patient population.
Opinion Statement:
Currently available data suggest that patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI) with stenting who do not continue oral anticoagulation are at increased risk for mortality and morbidity. In this patient population, therapy directed at reducing both thromboembolism (via oral anticoagulation) and stent thrombosis (via dual antiplatelet therapy) is necessary but is associated with an increased risk for bleeding. For patients with a high risk for thromboembolism based on published AF risk scores, the use of bare metal stents is recommended to minimize the duration of triple therapy. During the time period when triple therapy is used, the International Normalized Ratio (INR) should be maintained at the lower end of therapeutic range (2.0), and lower dose aspirin should be used. Finally, as newer oral anticoagulation agents such as dabigatran and rivaroxaban become available, further research will be required to determine their safety and efficacy in patients with AF undergoing PCI with stenting.
Related Concept Videos
Acute Coronary Syndrome IV: Interprofessional Care
Cardiac Catheterization I: Pre-Procedure Overview
Venous Thrombosis III: Interprofessional Care
Cardiac Catheterization II: Right Heart Catheterization
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Cardiac Catheterization III: Left Heart Catheterization

